. Author manuscript; available in PMC: 2024 Jun 1.

Published in final edited form as: Gynecol Oncol. 2023 May 4;173:130–137. doi: 10.1016/j.ygyno.2023.03.018

Table 2.

Disease progression and survival.

Treatment		Age < 70 Median in months (95%CI)	Age ≥ 70 Median in months (95%CI)	P	Adjusted Hazard Ratio (95%CI, P)
Carboplatin + Paclitaxel x8C	PFS	16.3 (15.2, 17.5)	14.8 (13.1, 17.7)	0.052	1.18 (0.95,1.46, 0.13)
Carboplatin + Paclitaxel x8C	OS	45.2 (40.4, 51.7)	36.6 (31.4, 43.4)	0.014	1.28 (1.01, 1.62, 0.041)
All arms	PFS	16.0 (15.4, 16.6)	15.1 (14.2, 15.9)	0.014	1.10 (1.00, 1.20, 0.056)
All arms	OS	45.0 (42.6, 46.9)	37.2 (33.6, 40.3)	<0.001	1.21 (1.09, 1.34, <0.001)

Cox proportional hazards models were performed by age group and adjusted for histology, performance status, treatment, stage, residual disease and grade.